Does Haematological Toxicity Increase with the Use of Lipophilic Chemotherapeutic Agents in Obese Breast Cancer Patients?
Duygu Bayir Garbioglu11Department of Medical Oncology, Zonguldak Bulent Ecevit University Faculty of Medicine, Zonguldak, Türkiye
Objectives: In our study, we aimed to investigate the relation between obesity and haematological toxicities evaluated after chemotherapy treatment with lipophilic chemotherapy given according to actual body surface area in breast cancer (Bca) patients with different stages and subtypes and its reflection on overall survival. Methods: 419 patients who received lipophilic chemotherapy regimens as the first serial chemotherapy regimen, who were not treated with primary granulocyte colony-stimulating factor (G-CSF) and whose haematological parameters were evaluated after the first course of treatment were included in the study. Results: It was found that 36.8% of 419 patients included in the study were obese. There was no difference between the groups in baseline clinicopathological characteristics except for age. There was a positive correlation between age and BMI values (r=0.254 p<0.001). Grade 3 and grade 4 neutropenia were observed more frequently in normal/underweight patients (p<0.05). Multivariate cox regression analysis showed that grade 3 thrombocytopenia affected survival 17.398 and grade 4 thrombocytopenia affected survival 14.004 times more negatively than grade 0 thrombocytopenia (p<0.001, p<0.001, respectively). Conclusion: No increase in toxicity or worsening of survival was observed with lipophilic chemotherapy agents given according to actual BSA in obese BCa patients with different stages and immunohistochemical subtypes. Keywords: Breast cancer, chemotherapy toxicity, obesity, lipophilic agents
Cite This Article
Garbioglu D. Does Haematological Toxicity Increase with the Use of Lipophilic Chemotherapeutic Agents in Obese Breast Cancer Patients?. EJMI. 2024; 8(1): 1-7
Corresponding Author: Duygu Bayir Garbioglu